|
Volumn 35, Issue 4, 2000, Pages 903-906
|
Optimal management of non-ST segment elevation myocardial infarction remains unclear
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ABCIXIMAB;
ACETYLSALICYLIC ACID;
ANTILIPEMIC AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CALCIUM ANTAGONIST;
CREATINE KINASE;
DALTEPARIN;
EPTIFIBATIDE;
HEPARIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
HYPOCHOLESTEROLEMIC AGENT;
LINOLENIC ACID;
LOW DENSITY LIPOPROTEIN CHOLESTEROL;
LOW MOLECULAR WEIGHT HEPARIN;
NITRATE;
OMEGA 3 FATTY ACID;
PLACEBO;
PRAVASTATIN;
SIMVASTATIN;
TIROFIBAN;
ANGINA PECTORIS;
ANGIOCARDIOGRAPHY;
BLOOD CLOT LYSIS;
CLINICAL TRIAL;
CONSERVATIVE TREATMENT;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
EARLY DIAGNOSIS;
ELECTROCARDIOGRAM;
FIBRINOLYTIC THERAPY;
HEART CATHETERIZATION;
HEART DEATH;
HEART INFARCTION;
HEART MUSCLE ISCHEMIA;
HEART MUSCLE REVASCULARIZATION;
HEART REINFARCTION;
HUMAN;
MORTALITY;
PRIORITY JOURNAL;
Q WAVE;
RECURRENT DISEASE;
REVIEW;
ST SEGMENT ELEVATION;
TRANSLUMINAL CORONARY ANGIOPLASTY;
UNSTABLE ANGINA PECTORIS;
|
EID: 0034653685
PISSN: 07351097
EISSN: None
Source Type: Journal
DOI: 10.1016/S0735-1097(99)00636-1 Document Type: Article |
Times cited : (4)
|
References (16)
|